Impact GLP-1 Agonists Following Bariatric
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: cardiovascular, sleep
- Who it enrolls
- age 18 Years to no upper limit; no BMI minimum stated; conditions: Morbid Obesity; Metabolic Syndrome; Diabetes Mellitus; Hypertension
- Interventions
- GLP-1 receptor agonist
- Conditions
- Morbid Obesity; Metabolic Syndrome; Diabetes Mellitus; Hypertension; Obstructive Sleep Apnea of Adult
- Phase and size
- Phase 4 · 150 participants
- Dates
- Start 2024-02-01
Primary completion 2028-07 - Sponsor
- University of Missouri-Columbia (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Effect of GLP1-RA on weight loss6 months
- Effect of GLP1-RA on circulating bile acids and metabolites6 months
- Effector of GLP1-RA on gut microbiome diversity6 months
- Effect of GLP1-RA on satiety and hunger6 months
- Effect of GLP1-RA on Glycemic control6 months
02Eligibility
Who can take part
Inclusion Criteria: 1. Greater than 18 years of age 2. Participation in care by one of the surgeons at MU Health Care 3. Undergoing surgical weight loss through the Weight Management and Metabolic Center 4. Body mass index of 30-80 kg/m2 5. Meet insurance criteria, as set forth by the patient's insurance policy, to qualify for coverage for weight loss surgery or as a self-pay patient for the weight loss procedure 6. Planned laparoscopic Roux-en-Y gastric bypass, sleeve gastrectomy, revisional weight loss surgery, or duodenal switch or modification of. If patients are not willing to be randomized they will not be enrolled as randomized but can still participate having samples collected. 7. Willingness to have blood collected before and after surgical procedure at defined points or at minimum have clinical data collected. 8. Willingness to have clinical data entered into a prospective database 9. Additional specimens collected as stated in the protocol will be offered but collection not mandated. 5\. Taking a GLP-1 agonist as part of their routine medical care apart from any planned surgical procedure. The current standard of care regarding continuation or discontinuation of GLP-1 agonists has not been established and is at the discretion of members of the patient's medical team but to be included the patient and medical care team must be willing to continue or discontinue the GLP-1 agonist after surgery depending on the randomized group. Exclusion Criteria: 1. Pregnant patient 2. Desire to not participate 3. Age less than 18 4. Patient fails to fulfill insurance mandated criteria and is not interested in paying cash for their procedure 5. Not taking a GLP-1 agonist as part of standard medical care 6. Unwilling to follow-up at required postoperative visits 7. Unwilling to stop GLP-1 agonist if randomized into group to stop GLP-1 agonist or unwilling to continue the GLP-1 agonist if randomized into that respective group. If chooses to continue or discontinue the medication apart from randomization the patient can still participate as a non-randomized participant
03Change log
Registry changes
No changes recorded since the trial was added.